b) recovering from said host cell an antibody comprising a heavy chain and a light chain, wherein the polypeptide sequence of said heavy chain is given by SEQ ID NO: 9 and the polypeptide sequence of said light chain is given by SEQ ID NO: 10.

~~In another aspect there is provided an antibody produced by the process as disclosed above.~~

In another aspect there is provided a pharmaceutical composition comprising an antibody as disclosed above and one or more pharmaceutically acceptable carriers, diluents or excipients.

In another aspect there is provided use of an antibody as disclosed above in the manufacture of a medicament for the treatment or prevention of an autoimmune or inflammatory condition, wherein the condition is selected from the group consisting of multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, ankylosing spondylitis, graft-versus-host disease, lupus and metabolic syndrome.

In another aspect there is provided use of an antibody as disclosed above in the manufacture of a medicament for treating or preventing cancer.

In another aspect there is provided an antibody as disclosed above for use in therapy.

~~In another aspect there is provided an antibody as disclosed above for use in the treatment of an autoimmune or inflammatory condition, wherein the condition is selected from the group consisting of multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, ankylosing spondylitis, graft-versus-host disease, lupus and metabolic syndrome.~~

~~In another aspect there is provided an antibody as disclosed above for use in the treatment of cancer.~~

Detailed Disclosure

The present invention provides an antibody that binds to the p19 subunit of human IL-23 comprising a light chain and a heavy chain, wherein the light chain comprises a light chain variable region (LCVR) and the heavy chain comprises a heavy chain variable region (HCVR), wherein the LCVR comprises amino acid sequences LCDR1, LCDR2, and LCDR3, and the HCVR comprises amino acid sequences HCDR1, HCDR2, and HCDR3, wherein LCDR1 is SEQ ID NO:4, LCDR2 is SEQ ID NO:5, LCDR3 is SEQ ID NO:6, HCDR1 is SEQ ID NO:1, HCDR2 is SEQ ID NO:2, and HCDR3 is SEQ ID NO:3.

In an embodiment of the present invention, the antibody comprises a light chain and a heavy chain, wherein the light chain comprises a light chain variable region (LCVR) and the

a) cultivating a recombinant host cell comprising a first polynucleotide sequence encoding the polypeptide sequence given by SEQ ID NO: 9 and a second polynucleotide sequence encoding the polypeptide sequence given by SEQ ID NO: 10, under conditions such that said polypeptide sequences are expressed; and

b) recovering from said host cell an antibody comprising a heavy chain and a light chain, wherein the polypeptide sequence of said heavy chain is given by SEQ ID NO: 9 and the polypeptide sequence of said light chain is given by SEQ ID NO: 10.

~~18. An antibody produced by the process of claim 16 or claim 17.~~

~~19~~18. A pharmaceutical composition comprising an antibody according to any one of claims 1-5 ~~and 18~~ and one or more pharmaceutically acceptable carriers, diluents or excipients.

~~20~~19. The use of an antibody according to any one of claims 1-5 ~~and 18~~ in the manufacture of a medicament for the treatment or prevention of an autoimmune or inflammatory condition, wherein the condition is selected from the group consisting of multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, ankylosing spondylitis, graft-versus-host disease, lupus and metabolic syndrome.

~~21~~20. The use of an antibody according to any one of claims 1-5 ~~and 18~~ in the manufacture of a medicament for treating or preventing cancer.

~~22~~21. The use according to claim ~~21~~20, wherein the cancer is melanoma, colon, ovarian, head and neck, lung, breast, or stomach cancer.

~~23~~22. An antibody according to any one of claims 1-5 ~~and 18~~ for use in therapy.

24. An antibody according to any one of claims 1-5 and 18 for use in the treatment of an autoimmune or inflammatory condition, wherein the condition is selected from the group consisting of multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, ankylosing spondylitis, graft-versus-host disease, lupus and metabolic syndrome.

25. An antibody according to any one of claims 1-5 and 18 for use in the treatment of cancer.

26. An antibody for use according to claim 25, wherein the cancer is melanoma, colon, ovarian, head and neck, lung, breast, or stomach cancer.